» Articles » PMID: 39062908

Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jul 27
PMID 39062908
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmunity refers to an organism's immune response against its own healthy cells, tissues, or components, potentially leading to irreversible damage to vital organs. Central and peripheral tolerance mechanisms play crucial roles in preventing autoimmunity by eliminating self-reactive T and B cells. The disruption of immunological tolerance, characterized by the failure of these mechanisms, results in the aberrant activation of autoreactive lymphocytes that target self-tissues, culminating in the pathogenesis of autoimmune disorders. Genetic predispositions, environmental exposures, and immunoregulatory disturbances synergistically contribute to the susceptibility and initiation of autoimmune pathologies. Within the realm of immune therapies for autoimmune diseases, cytokine therapies have emerged as a specialized strategy, targeting cytokine-mediated regulatory pathways to rectify immunological imbalances. Proinflammatory cytokines are key players in inducing and propagating autoimmune inflammation, highlighting the potential of cytokine therapies in managing autoimmune conditions. This review discusses the etiology of autoimmune diseases, current therapeutic approaches, and prospects for future drug design.

Citing Articles

Development of Anti-Inflammatory Agents Utilizing DC-SIGN Mediated IL-10 Secretion in Autoimmune and Immune-Mediated Disorders: Bridging Veterinary and Human Health.

Baek H, Yang S, Kim S, Lee Y, Park H, Park M Int J Mol Sci. 2025; 26(5).

PMID: 40076949 PMC: 11901132. DOI: 10.3390/ijms26052329.


Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders.

Sivalingam A Clin Rev Allergy Immunol. 2025; 68(1):14.

PMID: 39932617 DOI: 10.1007/s12016-025-09022-9.


Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.

Parvin N, Joo S, Mandal T J Funct Biomater. 2025; 16(1).

PMID: 39852580 PMC: 11766201. DOI: 10.3390/jfb16010024.


Advances in bio-polymer coatings for probiotic microencapsulation: chitosan and beyond for enhanced stability and controlled release.

Edo G, Mafe A, Razooqi N, Umelo E, Gaaz T, Isoje E Des Monomers Polym. 2025; 28(1):1-34.

PMID: 39777298 PMC: 11703421. DOI: 10.1080/15685551.2024.2448122.


An L-shaped association between lymphocyte-to-monocyte ratio and erectile dysfunction in NHANES 2001-2004.

Shan D, Yan C, Jia Z Sci Rep. 2025; 15(1):857.

PMID: 39757263 PMC: 11701207. DOI: 10.1038/s41598-025-85261-2.


References
1.
OShea J, Gadina M, Schreiber R . Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109 Suppl:S121-31. DOI: 10.1016/s0092-8674(02)00701-8. View

2.
Vieira S, Pagovich O, Kriegel M . Diet, microbiota and autoimmune diseases. Lupus. 2014; 23(6):518-26. PMC: 4009622. DOI: 10.1177/0961203313501401. View

3.
Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T . Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A. 1996; 93(1):407-11. PMC: 40247. DOI: 10.1073/pnas.93.1.407. View

4.
Taniguchi K, Wu L, Grivennikov S, de Jong P, Lian I, Yu F . A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015; 519(7541):57-62. PMC: 4447318. DOI: 10.1038/nature14228. View

5.
Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View